Perindopril
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1993
- First approval year
- 1993
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Perindopril
- Molecular weight
- 368.47
- Structure (SMILES)
- CCC[C@H](N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)OCC
- (2S,3aS,7aS)-1-[(S)-N-[(S)-1-Carboxybutyl]alanyl]hexahydro-2-indolinecarboxylic acid, 1-ethyl ester
- 1h indole 2 carboxylic acid 1 2 1 ethoxycarbonyl butyl amino 1 oxopropyl octahydro 2s 1 r r 2 alpha 3a beta 7a beta
- 1H-INDOLE-2-CARBOXYLIC ACID, 1-(2-((1-(ETHOXYCARBONYL)BUTYL)AMINO)-1-OXOPROPYL)OCTAHYDRO-, (2S-(1(R*(R*)),2.ALPHA.,3A.BETA.,7A.BETA.))-
- 2s 3as 7as 1 s n s 1 carboxybutyl alanyl hexahydro 2 indolinecarboxylic acid 1 ethyl ester
- atorvastatin perindopril
- mcn a 2833
- MCN-A-2833
- perindopril
- Perindopril
- Perindopril (T1)
- perindopril [INN]
- PERINDOPRIL [MART.]
- PERINDOPRIL [MI]
- PERINDOPRIL [USAN]
- PERINDOPRIL [VANDF]
- Perindopril [WHO-DD]
- perindopril inn
- perindopril mart
- perindopril mi
- Perindopril Oral Tablet
- Perindopril tablet
- perindopril usan
- perindopril vandf
- perindopril who dd
- s 9490
And 1 more, listed on the interactive page.
- ATC classification codes
- C09AA04
Sources for recorded values
- CAS registry numbers
- 82834-16-0
- ChEMBL ID
- CHEMBL1581
- InChIKey
- IPVQLZZIHOAWMC-QXKUPLGCSA-N
- RxNorm IDs (RxCUI)
- 54552
- FDA ingredient codes (UNII)
- Y5GMK36KGY
- 107807
- 40466996
- Applicant
- SYMPLMED PHARMS LLC
- Approval date
- 30 Dec 1993
- Application number
- NDA020184
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
- Boxed warning
- Yes
- Pharmacology name
- perindopril
- Type
- Synthetic organic
- Drug name stem
- -pril
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
Mechanisms of action
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- Angiotensin-converting enzyme
- Gene symbol
- ACE
- Protein identifier
- P12821
- Primary target
- Yes
Open Targets mechanisms
- Mechanism
- Angiotensin-converting enzyme inhibitor
- Action type
- Inhibitor
- Target
- Angiotensin-converting enzyme
DrugCentral mechanisms
- Action type
- Inhibitor
- Gene symbol
- ACE
- Protein identifier
- P12821
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Cardiovascular Diseases
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000319
- Subject identifier
- D002318
- Condition
- Cardiomyopathy, Dilated
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000407
- Subject identifier
- D002311
- Condition
- Hypertension
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000537
- Subject identifier
- D006973
- Condition
- Stress Disorders, Post-Traumatic
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001358
- Subject identifier
- D013313
- Condition
- Aortic Aneurysm, Abdominal
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004214
- Subject identifier
- D017544
- Condition
- Amphetamine-Related Disorders
- Highest recorded phase
- 1
- Condition identifier
- EFO:0004701
- Subject identifier
- D019969
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000654
- Subject identifier
- D009369
- Condition
- Substance-Related Disorders
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0002491
- Subject identifier
- D019966
- Condition
- Alzheimer Disease
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0004975
- Subject identifier
- D000544
- Condition
- Diabetes Mellitus, Type 2
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0005148
- Subject identifier
- D003924
- Condition
- Breast Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0007254
- Subject identifier
- D001943
- Condition
- Marfan Syndrome
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0007947
- Subject identifier
- D008382
- Condition identifier
- EFO_0000319
- Condition identifier
- EFO_0000407
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000537
- Condition identifier
- EFO_0004214
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000654
- Highest recorded phase
- 2
- Condition identifier
- HP_0000822
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0001134
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002525
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004975
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004981
- Condition identifier
- MONDO_0004995
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005010
- Condition identifier
- MONDO_0005016
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005044
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005068
- Condition identifier
- MONDO_0005148
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005252
- Condition identifier
- MONDO_0005419
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0007254
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007947
- Highest recorded phase
- 3
Open Targets warnings
- Warning
- Black Box Warning
- Effect
- teratogenicity
- Country
- United States
- Event
- acute kidney injury
- Reports
- 432
- Reporting signal score
- 789.02
- Event
- angioedema
- Reports
- 74
- Reporting signal score
- 70.23
- Event
- anuria
- Reports
- 27
- Reporting signal score
- 48.1916
- Event
- aptyalism
- Reports
- 12
- Reporting signal score
- 41.6842
- Event
- asthma
- Reports
- 104
- Reporting signal score
- 125.835
- Event
- atrial enlargement
- Reports
- 16
- Reporting signal score
- 75.6895
- Event
- atrial fibrillation
- Reports
- 108
- Reporting signal score
- 108.783
- Event
- autoimmune nephritis
- Reports
- 10
- Reporting signal score
- 41.0364
- Event
- back injury
- Reports
- 19
- Reporting signal score
- 36.4031
- Event
- blood count abnormal
- Reports
- 37
- Reporting signal score
- 56.3166
- Event
- blood pressure systolic abnormal
- Reports
- 16
- Reporting signal score
- 48.0892
- Event
- bradycardia
- Reports
- 91
- Reporting signal score
- 86.1917
- Event
- breath sounds abnormal
- Reports
- 20
- Reporting signal score
- 45.1114
- Event
- cardiac failure
- Reports
- 79
- Reporting signal score
- 85.3113
- Event
- cardiac failure chronic
- Reports
- 38
- Reporting signal score
- 117.051
- Event
- cardiac murmur
- Reports
- 45
- Reporting signal score
- 101.704
- Event
- cardiogenic shock
- Reports
- 28
- Reporting signal score
- 44.7238
- Event
- cardiomyopathy
- Reports
- 46
- Reporting signal score
- 76.5705
- Event
- cholestasis
- Reports
- 38
- Reporting signal score
- 42.3638
- Event
- coma scale abnormal
- Reports
- 43
- Reporting signal score
- 124.038
- Event
- confusional state
- Reports
- 86
- Reporting signal score
- 41.5822
- Event
- congenital bladder anomaly
- Reports
- 11
- Reporting signal score
- 51.3516
- Event
- conjoined twins
- Reports
- 19
- Reporting signal score
- 107.775
- Event
- cough
- Reports
- 186
- Reporting signal score
- 146.571
- Event
- decreased gait velocity
- Reports
- 10
- Reporting signal score
- 56.9908
And 61 more, listed on the interactive page.
- NCT00145925
- NCT00202553
- NCT00202592
- NCT03246555
- NCT00249665
- NCT01062451
- NCT00485368
- NCT01118520
- NCT01583114
- NCT01948232
- NCT02085265
- NCT02308202
- NCT04588935
- Dose
- 4 mg
- Route
- Oral
- How often
- Once daily
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 2
- Polar surface area
- 95.94
- Calculated partition coefficient (ALogP)
- 1.94
- Calculated partition coefficient (XLogP)
- 0.9
- Prodrug
- Yes
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 8
- Heavy atoms
- 26
- Molecular formula
- C19H32N2O5
- Monoisotopic mass
- 368.23112213
- Natural product
- Yes
- Recorded assays
- 1,261
- Active assays
- 7
- Confirmatory
- Other
- Screening
- Angiotensin-Converting Enzyme Inhibitors
- Antihypertensive Agents
These details could not be displayed.
Related records
Trials (60)
- A Study in Healthy Men That Tests if Taking BI 1265162 by Mouth, Intravenously, or Inhaled Influences the Amount of BI 1265162 in the Blood
- A Study in Healthy People to Compare 2 Different Formulations of BI 1015550 Taken With or Without Food
- A Study in Healthy People to Test if Taking Different Formulations of BI 425809 Tablets Influences the Amount of BI 425809 in the Blood
- A Study on Whether Patients Prefer the Spiriva® Respimat® or the Spiriva® Handihaler® for Treating Their Chronic Obstructive Pulmonary Disease (COPD)
- A Study to Evaluate the Pharmacokinetics Similarity of CBP-201 in Healthy Adult Chinese Subjects
- ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension
- An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence
- Angiotensin Receptor Blocker Combined With Calcium Antagonist Evaluation of Safety and Lowering of Systolic Blood Pressure Study
- Assessment of the Efficacy and Tolerability of the Fixed-dose Combination of Bisoprolol/Perindopril
- Bioavailability and Safety of Two Oral Fixed Dose Preparations Containing 18 mg Ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) Versus Reference Dosing (Weight Based) Containing 6 mg Ivermectin (REVECTINA®, Abbott Laboratórios do Brasil Ltda, Brazil)
- Bioequivalence Study of Perindopril /Amlodipine/Indapamide 8 mg (10 mg)/2.5 mg/10 mg Tablets in Healthy Volunteers Under Fasting Conditions
- Bioequivalence Study of Perindopril Tablets in Healthy Volunteers Under Fasting Conditions
- Bioequivalence Study of Two Formulations of Perindopril 4 mg Tablet Under Fasting Condition
- Bioequivalence Study to Compare Selexipag 400 Microgram Film Coated Tablets Versus Uptravi® (Selexipag) 400 Microgram Film Coated Tablets
- Blood Pressure and Glucose Lowering for the Prevention of Vascular Disease in High Risk Patients With Type 2 Diabetes
- Chronic Subdural Hematoma - Reduction of Recurrence by Treatment With Angiotensin Converting Enzyme Inhibitors
- Compare Safety and Pharmacokinetic Properties of Surfolase Capsule(Acebrophylline 100mg) and Surfolase CR(200mg)
- Comparison of Medical Therapies in Marfan Syndrome.
- Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood Pressure
- Comparison of Three Combination Therapies in Lowering Blood Pressure in Black Africans
Approved for (1)
In development for (11)
- Abdominal aortic aneurysm Phase 2
- Alzheimer disease Phase 2
- Breast cancer Phase 2
- Childhood malignant neoplasm Phase 2
- Dilated cardiomyopathy Phase 3
- Hypertensive disorder Phase 3
- Marfan syndrome Phase 3
- Methamphetamine dependence Phase 1
- Post-traumatic stress disorder Phase 1
- Substance abuse Phase 1
- Type 2 diabetes mellitus Phase 3
Targets (1)
- ACE Angiotensin-converting enzyme inhibitor